Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTIFAN-1 phase 2 study of BCMA-targeted LCAR-B38M CAR-T in relapsed or refractory multiple myeloma in China
CTR20181007Phase 2Terminated
- Sponsor
- Legend Biotech Corporation
- Start
- Feb 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of ciltacabtagene autoleucel in multiple myeloma (MM), sponsored by Legend Biotech Corporation. Started Feb 2019; status: terminated.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20181007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181007.